Definitive Contract HHSO100201700026C
Award Date 9/14/17
Potential Completion Date 6/30/24
Potential Value $44M
Ultimate Awardee
Not listed NAICS Category
Federal Contract Vehicle
- Not listed
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed Pricing Type
Firm Fixed Price
Place of Performance
East Hanover, NJ 07936, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
1
Legislative Mandate
Not listed National Interest Action
Not listed Research Type
Not listed Primary Consortia Member
Not listed Similar Awards
- This is a delivery order for the pharmaceutical products Pluvicto and Lutathera, awarded to Novartis Pharmaceuticals Corporation, a large foreign-owned pharmaceutical manufacturer. The $3,387,019.66 fixed-price contract with economic price adjustment was awarded by the Defense Health Agency, a defense agency, and has an ultimate completion date of September 30, 2025. The award is not associated with a set-aside. Novartis holds a $5.4 billion Federal Supply Schedule contract for pharmaceuticals...
- The Department of Veterans Affairs (VA) awarded a $283,526.57 delivery order to Novartis Pharmaceuticals Corporation, doing business as NPS, for emergency drug orders to support the Tennessee Valley Healthcare System (TVHS). This order was placed against Novartis' Federal Supply Schedule (FSS) 61-IB contract for pharmaceuticals and drugs, which has a total potential value of $5.4 billion and runs through August 2025. Novartis, a foreign-owned, for-profit manufacturer, has provided specialized...
- This is a federal contract award to Novartis Pharmaceuticals Corporation, a large foreign-owned pharmaceutical manufacturer, for the delivery of the drug Fabhalta 200 mg. The contract, valued at $33,838.23, is a firm fixed-price delivery order awarded by the Department of Veterans Affairs (VA) under the Pharmaceuticals and Drugs Federal Supply Schedule (FSS-61-IB). The contract has an ultimate completion date of August 28, 2025 and does not utilize a small business set-aside designation....
- This is a delivery order for the radiopharmaceutical Pluvicto awarded to Novartis Pharmaceuticals Corporation, a large foreign-owned pharmaceutical manufacturer, by the Veterans Integrated Service Network 12, a civilian agency. The delivery order has a base period plus one option year, with a total ceiling value of $1,661,457.00. The contract is a firm fixed-price delivery order under Novartis' Federal Supply Schedule (FSS-61-IB) contract for pharmaceuticals and drugs. Novartis also holds a...
- This contract was awarded by the Department of Health and Human Services Office of the Assistant Secretary for Preparedness and Response (ASPR) to Amgen Inc., a for-profit manufacturer, to develop an NPLATE administration kit for the treatment of approved indications, including Acute Radiation Syndrome (ARS). The contract is a definitive, cost-sharing contract with a potential value of $7,290,923.50 and a completion date of August 27, 2026. The contract award is not associated with a set-aside...
- Novartis Pharmaceuticals Corporation, doing business as NPS, was awarded a $334,446.40 firm fixed-price delivery order for PLUVICTO 2026 Cleveland by the Department of Veterans Affairs' Veterans Integrated Service Network 10 on January 5, 2026, with an ultimate completion date of December 31, 2026. The contract, which was not designated as a small business set-aside, is for delivery to East Hanover, New Jersey. This delivery order falls under Novartis' existing Blanket Purchase Agreement...
- This is a federal contract award from the U.S. Department of Veterans Affairs (VA) to Novartis Vaccines And Diagnostics, Inc. for the delivery of drugs and biologicals. The contract has a ceiling value of $262,467.00 and is a Firm Fixed Price Delivery Order. The contract does not have a set-aside designation. The award was made on May 16, 2007, with an ultimate completion date of September 11, 2007. The place of performance is Phoenix, Arizona. Novartis Vaccines And Diagnostics, Inc. is a...
- This federal contract award is for the delivery of FABHALTA 200 MG, a pharmaceutical product, to the Department of Veterans Affairs (VA) through Novartis Pharmaceuticals Corporation's Federal Supply Schedule (FSS) contract. The contract has a ceiling value of $33,838.23 and a period of performance ending on March 21, 2025. The contract was awarded on March 14, 2025 and is a firm fixed-price delivery order, with no set-aside designation. Novartis, a foreign-owned, for-profit manufacturer of...
- On November 7, 2025, the Department of Veterans Affairs' Veterans Integrated Service Network 12 (VISN 12) awarded a delivery order valued at $365,520.54 to Novartis Pharmaceuticals Corporation for PLUVICTO radiopharmaceutical. This firm fixed-price contract represents a delivery order issued against Novartis' existing Pharmaceuticals and Drugs Federal Supply Schedule (FSS-61-IB) and will be performed in Chicago, Illinois, with an ultimate completion date of January 31, 2026. The award utilizes...
- This contract awarded to Amgen Inc. by the Department of Health and Human Services Office of the Assistant Secretary for Preparedness and Response (ASPR) provides $33,719,968.24 to advance the development of romiplostim for the treatment of hematopoietic subsyndrome-acute radiation syndrome (HS-ARS) and chemotherapy-induced thrombocytopenia (CIT), as well as a drug delivery device feasibility project. The contract includes a $3,711,014.00 supplement to CLIN 002 and the de-obligation of...